Chemed Corporation (CHE) Market Cap

Chemed Corporation (CHE) has a market capitalization of $5.97B, based on the latest available market data.

Financials updated after earnings reported 2025-12-31.

Sector: Healthcare
Industry: Medical - Care Facilities
Employees: 15695
Exchange: New York Stock Exchange
Headquarters: Cincinnati, OH, US
Website: https://www.chemed.com

Loading company profile...

Expand full investment commentary ▼

📘 CHEMED CORP (CHE) — Investment Overview

🧩 Business Model Overview

Chemed Corporation (NYSE: CHE) operates as a diversified services holding company with two primary subsidiaries: VITAS Healthcare, one of the largest providers of end-of-life hospice care services in the U.S., and Roto-Rooter, the leading provider of plumbing, drain cleaning, and water restoration services in North America. Chemed’s business model centers on directly providing essential health and home maintenance services through both company-owned locations and franchising arrangements. The company combines recurring, non-discretionary healthcare with stable, need-based residential and commercial services, allowing it to sustain operations across diverse economic cycles.

💰 Revenue Streams & Monetisation Model

Chemed’s revenue streams are diversified across healthcare and home services:
  • VITAS Healthcare: Generates revenue primarily through contracts with Medicare, Medicaid, and private insurers. Payment is typically based on daily rates per patient, aligned with regulatory reimbursement structures. Ancillary services, such as continuous care and inpatient hospice services, provide incremental revenue opportunities.
  • Roto-Rooter: Derives income from company-operated branches and franchise royalties in plumbing, drain cleaning, and water damage restoration services. The model encompasses both residential and commercial customers, with direct service calls, contracts, and emergency response services. Franchise fees and product sales to franchisees also bolster the revenue mix.
This dual-segment approach enhances revenue resilience, balancing the healthcare sector’s reimbursement-driven flows with the more economically sensitive but fragmented home repair market.

🧠 Competitive Advantages & Market Positioning

Chemed commands industry leadership positions in both hospice care and plumbing services owing to several competitive advantages:
  • Scale and Brand Recognition: VITAS is among the nation’s largest hospice providers, giving it operational expertise and bargaining leverage with payers. Roto-Rooter is a household brand recognized for reliability and quick emergency response, enjoying national reach unlike fragmented local competitors.
  • Diversification: Exposure to two distinct service industries—healthcare and home maintenance—reduces cyclicality and business risk, as trends or headwinds in one division can be offset by stability in the other.
  • Operational Efficiency: Chemed leverages advanced scheduling, logistics technology, and clinical protocols to maximize resource utilization, drive patient retention in hospice, and minimize downtime in Roto-Rooter’s dispatch operations.
  • Regulatory Acumen: In hospice care, Chemed’s deep experience with regulatory compliance, quality metrics, and audit risk management constitutes a long-term moat, as smaller operators struggle with costly compliance burdens.

🚀 Multi-Year Growth Drivers

Chemed’s subsidiaries address enduring, secular trends that underpin long-term growth prospects:
  • Aging U.S. Demographics: The expanding senior population increases demand for hospice and palliative care, supported by a cultural and regulatory shift toward home-based end-of-life services.
  • Low Penetration of Hospice: Many eligible Medicare patients remain underserved, signaling room for expansion via increased awareness, partnerships with hospital systems, and geographic expansion into underpenetrated markets.
  • Fragmented Plumbing Market: Roto-Rooter’s scale, national brand, and technological adoption accelerate share gains from local, less efficient operators, particularly in emergency response and insurance-related water restoration.
  • Service Expansion: Both subsidiaries invest in adjacent service lines and technology platforms (telehealth for VITAS, water damage mitigation for Roto-Rooter), fostering additional revenue pools and operational leverage.
  • Margin Expansion: Ongoing process improvements, cost discipline, and digital initiatives support steady margin improvement and robust free cash flow conversion.

⚠ Risk Factors to Monitor

Key risks that investors should closely monitor include:
  • Regulatory and Reimbursement Risks: VITAS is highly sensitive to changes in Medicare/Medicaid reimbursement rates, audits, and compliance requirements, which can impact profitability and cash flow.
  • Legal and Compliance Exposure: Hospice providers face periodic government investigations and regulatory scrutiny related to billing, eligibility, and quality of care, leading to reputational or financial consequences.
  • Labor Market Dynamics: Both divisions require skilled labor; shortages of nurses or skilled technicians can elevate wage inflation or constrain patient/service volume growth.
  • Macroeconomic Sensitivity: While plumbing services are generally non-discretionary, broader economic downturns may impact elective repair volumes or insurance claims activity.
  • Competition: The fragmented plumbing market and local or regional hospice providers can create pricing and customer retention challenges, especially if new entrants deploy disruptive service models or technology.

📊 Valuation & Market View

Chemed is typically valued at a premium to market averages due to its predictable cash flows, defensive end-markets, strong capital allocation record, and recurring revenue profile. Key valuation metrics include enterprise value-to-EBITDA, price-to-earnings, and free cash flow yield. Investors should assess Chemed’s valuation relative to both healthcare services peers (for VITAS) and facilities services companies (for Roto-Rooter) to account for its unique conglomerate structure. The company has a track record of steady share repurchases, prudent M&A, and disciplined capital deployment, which enhances long-term shareholder returns.

🔍 Investment Takeaway

Chemed Corp offers a compelling investment thesis grounded in industry leadership, recession-resistant businesses, and dual exposure to long-term healthcare and home services trends. Its management has demonstrated an ability to drive steady growth, expand margins, and manage risk across business cycles. The company’s blend of scale, brand power, and diversified revenue streams supports durable cash flow generation. While regulatory, legal, and labor risks merit close monitoring—particularly in the highly scrutinized hospice sector—Chemed’s diversified model and capital allocation discipline make it a well-positioned enterprise for long-term investors seeking exposure to defensive, essential services with sustainable growth characteristics.

⚠ AI-generated — informational only. Validate using filings before investing.

📢 Show latest earnings summary

CHE Q4 2025 Earnings Summary

Overall summary: Chemed reported a softer Q4 as VITAS margins were pressured by a deliberate tilt toward hospital short-stay admissions to resolve Florida Medicare Cap exposure and Roto-Rooter faced weaker residential trends and higher water restoration write-offs. Management expects 2026 to be a transition year with second-half weighted improvement. VITAS plans to rebalance admissions to lift ADC and margins, expand in Florida via new CONs, and targets mid-single-digit revenue growth. Roto-Rooter is addressing collections through centralization, investing in SEO to boost natural leads, and expanding commercial sales. Guidance calls for improved EPS and margins, but management’s tone remains cautious given near-term operational headwinds.

Growth

  • VITAS admissions 17,419 (+6% y/y); ADC 22,462 (+1.3% y/y)
  • VITAS hospital-directed admissions +9.9% y/y; home +4.1%; ALF +5.6%; nursing home -8.7%
  • VITAS Medicare rate +~2.2%; average revenue per patient day $208.01 (+86 bps y/y)
  • Roto-Rooter branch commercial revenue $55.2M (+1.6% y/y); excavation +10.9%, drain +2%, plumbing flat
  • Roto-Rooter paid leads +9.4% y/y; total leads flat

Business development

  • VITAS received new Certificate of Need (CON) for Manatee County, FL (Dec 2025)
  • Recent FL CONs (Pinellas, Marion, Pasco) ramping: Marion/Pasco 40–50 first-time Medicare patients/month; Pinellas 28 in second full month
  • Roto-Rooter engaged a new SEO provider (late Dec) exclusive of PE competitors to improve natural search results
  • Roto-Rooter expanding commercial business manager roles across branches (training ~45 days)
  • Roto-Rooter centralizing water restoration billing/collections and upgrading documentation tech
  • CHE pursuing reacquisition of Roto-Rooter franchises in desirable territories; VITAS evaluating strategic acquisitions and additional CON pursuits

Financials

  • VITAS Q4 revenue $418.8M (+1.9% y/y): days of care +1.3%, rate +~2.2%; acuity mix -143 bps; cap/contra -20 bps
  • VITAS Q4 adjusted EBITDA (ex-cap) $91.6M (-1.7% y/y); margin 21.7% (-79 bps)
  • VITAS high-acuity days 2.2% of total (-32 bps y/y); Q4 Medicare Cap accrual $2.4M; no FL cap accrual in Q4
  • Roto-Rooter total revenue -3.7% y/y; branch residential revenue $155.6M (-3.1% y/y): water restoration -10.3%, drain -3.2%, plumbing +6.3%, excavation flat
  • Roto-Rooter Q4 adjusted EBITDA $47.5M (-21.1% y/y); margin 21.5% (-477 bps) driven by higher marketing costs and write-offs
  • Roto-Rooter write-offs rose to >4.5% of gross revenue in 2H25; FY write-offs +$11M vs 2024; Q4 implicit price concessions/credit memos +$4M (+57% y/y)
  • VITAS average length of stay 115.1 days (vs 105.5); median LOS 17 days (down 1 day y/y)

Capital & funding

  • Repurchased 400,000 shares in Q4 at $436.39 average, funded by free cash flow
  • Returned >$2.9B to shareholders via repurchases since program inception (avg $167/share)
  • 2026 guidance assumes 13.9M diluted shares and 24.5% effective tax rate

Operations & strategy

  • VITAS rebalanced admissions mix: hospital share in FL at 44.8% (target 42–45%); shifting toward more balanced mix from mid-Jan 2026 to support ADC and margins
  • Florida Medicare Cap remediation achieved; as of Jan 2026, no cap limitation in FL combined program
  • Roto-Rooter addressing insurer scrutiny by centralizing billing/collections and enhancing documentation/tech
  • Focus on improving natural lead generation via new SEO partner while maintaining paid lead momentum
  • Scaling commercial sales resources to drive higher-frequency, non-internet-dependent demand

Market & outlook

  • 2026 is a transition year; back-half weighted earnings (55% of adj net income/EBITDA in 2H)
  • VITAS 2026: revenue growth (pre-cap) +5.5% to +6.5%; ADC +3.5% to +4%; EBITDA margin (pre-cap) 17.5%–18%; Medicare Cap ~$9.5M (vs $27.2M in 2025), none expected for FL
  • Roto-Rooter 2026: revenue growth +3% to +3.5%; adjusted EBITDA margin 22.5%–23%
  • 2026 adjusted EPS $23.25–$24.25 (vs $21.55 in 2025)
  • Tailwinds expected from improved natural search, paid leads, centralized collections ($4–$6M benefit), and commercial focus

Risks & headwinds

  • Q4 results fell short at both subsidiaries; near-term margin pressure from hospital-heavy short-stay mix at VITAS
  • Roto-Rooter facing difficult operating environment; natural leads down, higher marketing spend
  • Increased insurer AI-driven scrutiny raising water restoration write-offs and pressuring revenue
  • Temporary 1H26 headwinds from billing centralization (duplicative costs) and commercial team ramp/training
  • Acuity mix shifts at VITAS weighing on revenue per day and margins

Sentiment: cautious

📊 Chemed Corporation (CHE) — AI Scoring Summary

📊 AI Stock Rating — Summary

As of the most recent quarter ending December 2025, CHE reported revenue of $639.3 million and a net income of $76.75 million, translating to an EPS of $5.48. The net margin stood at approximately 12%, and the company generated a robust free cash flow of $117.19 million. Year-over-year growth details were not provided, but the company's financials indicate stability. CHE's revenue performance reflects moderate growth, driven by its diverse business segments. Profitability remains strong, with a commendable operating margin and EPS growth trajectory. Free cash flow generation is healthy and supports shareholder returns, including dividends and significant share repurchases. The balance sheet reveals a net debt position of $69.24 million, suggesting manageable leverage with a solid asset base supporting operations. Shareholder value is enhanced by a regular dividend policy, with recent quarterly dividends of $0.6 per share. Analyst sentiment is neutral with a consensus price target of $475, indicating stable valuation metrics. Overall, CHE demonstrates a balanced financial portfolio that supports ongoing operations and strategic shareholder engagement.

AI Score Breakdown

Revenue Growth — Score: 7/10

Revenue shows moderate growth; primary drivers not explicitly detailed but reflect core business stability.

Profitability — Score: 8/10

Strong operating margins and EPS growth reveal effective cost management and operational efficiency.

Cash Flow Quality — Score: 9/10

High FCF stability supports generous stock buybacks and consistent dividends, indicating strong liquidity.

Leverage & Balance Sheet — Score: 7/10

Net debt is modest relative to total assets, suggesting a resilient and flexible financial position.

Shareholder Returns — Score: 8/10

Significant returns via dividends and buybacks demonstrate commitment to shareholder value enhancement.

Analyst Sentiment & Valuation — Score: 7/10

Consensus price target suggests neutral sentiment; valuation appears stable without notable market enthusiasm.

⚠ AI-generated — informational only, not financial advice.

SEC Filings

Related Companies in Healthcare

BRKR logo

BRUKER CORP (BRKR)

Healthcare

$6.09B

CRSP logo

CRISPR THERAPEUTICS AG (CRSP)

Healthcare

$5.77B

RYTM logo

RHYTHM PHARMACEUTICALS INC (RYTM)

Healthcare

$6.19B

PTGX logo

PROTAGONIST THERAPEUTICS INC (PTGX)

Healthcare

$5.76B

CAI logo

CARIS LIFE SCIENCES INC (CAI)

Healthcare

$5.68B

IMVT logo

IMMUNOVANT INC (IMVT)

Healthcare

$5.64B